Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug–Drug Interaction Study of Dolutegravir With Once-Weekly Isoniazid and Rifapentine

BACKGROUND: Once-weekly isoniazid and rifapentine for 3 months is a treatment option in persons with human immunodeficiency virus and latent tuberculosis infection. This study aimed to examine pharmacokinetic drug–drug interactions between this regimen and dolutegravir, a first-line antiretroviral m...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Infect Dis
Auteurs principaux: Brooks, Kristina M, George, Jomy M, Pau, Alice K, Rupert, Adam, Mehaffy, Carolina, De, Prithwiraj, Dobos, Karen M, Kellogg, Anela, McLaughlin, Mary, McManus, Maryellen, Alfaro, Raul M, Hadigan, Colleen, Kovacs, Joseph A, Kumar, Parag
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2018
Sujets:
Articles and Commentaries
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6248641/
https://ncbi.nlm.nih.gov/pubmed/29415190
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/ciy082
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires